Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales

NEW YORK ─ DiaSorin said Thursday that its third quarter revenues rose 51 percent year over year, driven in part by a recovery in non-COVID-19 related test sales.

For the three months ended Sept. 30, the Saluggia, Italy-based company reported revenues of €343.5 million ($393.9 million) in revenues compared to €227.9 million in Q3 2020.

The firm said that its Q3 CLIA-test revenues rose 23 percent year over year to €140.4 million from €114.3 million. ELISA test revenues fell 11 percent year over year to €14.5 million from €16.3 million. Q3 molecular test revenues of €82.1 million were up 6 percent year over year from €77.8 million, and instruments sales and other revenues of €15.4 million dropped 21 percent year over year from €19.5 million. Luminex contributed €91.1 million to DiaSorin's Q3 revenues.

The company said its Q3 revenues grew 10 percent year over year excluding Luminex revenues.

DiaSorin completed the acquisition of Austin, Texas-based Luminex in July for $1.8 billion.

DiaSorin said in the recently completed quarter, it saw a strong recovery of non-COVID-19 related sales, which grew 8.4 percent year over year excluding Luminex revenues. The recovery of its non-COVID business was driven in particular by sales of latent tuberculosis tests as well as infectious disease, and Q3 sales of SARS-CoV-2 serology and molecular tests excluding Luminex revenues were €80.0 million, up 14 percent year over year compared to €70.4 million.

The company posted a Q3 net profit of €79.3 million compared to €67.8 million in Q3 2020.

Its Q3 R&D expenses rose 67 percent year over year to €20.8 million from €12.5 million, while its SG&A expenses increased 66 percent year over year to €85.9 million from €51.6 million.

DiaSorin said it had €327.7 million in cash and cash equivalents at the end of Q3.

For full-year 2021, the company expects year-over-year revenue growth of 40 percent at a constant exchange rate. Earlier this year, DiaSorin said it expected year-over-year revenue growth between 15 percent and 25 percent. In Q2, following the Luminex acquisition, DiaSorin said it anticipated 2021 revenues of approximately €1.2 billion.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.